Risk Profile Improvements

  • Material Weakness (improved) — Material weakness in IT general controls for CooperSurgical U.S. operations has been remediated; controls now deemed effective.
NASDAQ: COO COOPER COMPANIES, INC. 10-Q

Cooper logs $272M embryo-media litigation charge; IT controls fixed, U.K. tax appeal pending

Filed June 5, 2026 · Period ending April 30, 2026 · Compared to 10-Q May 30, 2025 · ~1 min read

Key Changes

  • high

    CooperSurgical recorded $271.6M net litigation expense ($324.1M liability less $52.5M insurance) for embryo culture media recall claims—over 140 lawsuits and 1,500 claimants now exceed available insurance coverage, swinging the segment to operating loss.

    Legal Proceedings / MD&A: Litigation verify on EDGAR →
  • high

    U.K. tax tribunal ruled against Cooper on 2014 Sauflon payroll tax dispute; company is appealing but faces potential liability of £71.7M plus interest if unsuccessful.

    Legal Proceedings verify on EDGAR →
  • high

    Material weakness in IT general controls for CooperSurgical U.S. operations has been remediated; disclosure controls now deemed effective as of April 30, 2026.

    Controls and Procedures verify on EDGAR →

2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.

Read 3 full reports/month free No card required. Takes 30 seconds.

Want to see a complete report first? Today's free report (HOTH 10-Q) is open in full — no account needed.

Partner

Trade COO commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.